BARDA DRIVe

About BARDA DRIVe

In 2019, the Biomedical Advanced Research and Development Authority (BARDA) expanded their Division of Research, Innovation, and Ventures (DRIVe) to stimulate investment and innovation in health security products and technologies. DRIVe provides technical and financial resources to entrepreneurs whose ideas have the potential to transform emergency preparedness, detection, and response.

NOBIC was selected as one of 13 sites in the DRIVe accelerator network to identify health security entrepreneurs and connect them with resources that will enable earlier treatment and warning for communities against outbreaks.

Continuous areas of interest for EZ-BAA applications:

• Infection Severity & Solving Sepsis: innovative technological approaches to empower both the patient and the healthcare provider.
• Beyond the Needle: (Alternative Routes of Administration for Vaccines) to make vaccinations easier to administer and more widely available.

Up to $749,000 in funding is available per technology with a required 30% cost share. Solicitation Details Here.

BARDA EZ-BAA 

DRIVe accelerates the development of new innovations and approaches that solve health security challenges and protect Americans from health security threats. Below are the current areas of interest for funding and partnership in the EZ-BAA.

NEW areas of interest for EZ-BAA applications: 

• AOI #8: Bringing Laboratory Testing to the Home: is seeking to support a full suite of at-home testing which could revolutionize diagnostics, chronic disease management, and even clinical research, providing better access to care and a more disaster-resilient health care system. Register for a webinar on this AOI on 9/22 here, or check out our events page!
• AOI #9: Digital Health Tools for Pandemic Preparedness: will support the development of novel digital technologies that can serve as the first line of defense and augment existing medical countermeasures. Such digital health tools, including smartphone apps, social networks, telehealth, or other web applications, are intended to provide broadly available nowcasting and rapid response solutions. Register for a webinar on this AOI on 10/6 here, or check out our events page!
• AOI #10: Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens: will support further verification and validation of existing NGS-based assays for detection of respiratory RNA viruses, and support them through FDA approval. The goal of this approach is to help to prepare the U.S. and potentially the world for future pandemics involving respiratory RNA pathogens. Register for a webinar on this AOI on 10/13 here, or check out our events page!
• AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2:  will support the development of Emergency Use Authorized (EUA), home-based in-vitro diagnostic assays that can detect SARS-CoV-2 in samples collected in a home setting. Please review the latest Easy Broad Agency Announcement (EZ-BAA) special instructions #14 for more information. Register for a webinar on this AOI on 9/29 here, or check out our events page 
• AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection:  will support technologies that can enable more widespread adoption of at-home testing, and (2) improvements on current technological limitations of diagnostic sensitivity/specificity and performance. Please review the latest Easy Broad Agency Announcement (EZ-BAA) special instructions #14 for more information. Register for a webinar on this AOI on 9/29 here, or check out our events page!